- First time presentations at a scientific congress of results from the two pivotal Phase III trials, LixiLan-L and LixiLan-O, with iGlarLixi
- Presentations in two oral sessions on Sunday, 12 June 2016
Copenhagen, 8 June 2016 – Zealand informs that new Phase III data will be presented on iGlarLixi, the fixed-ratio titratable combination of insulin glargine 100 Units/mL (Lantus®) and lixisenatide, at the upcoming 76th Scientific Sessions of the American Diabetes Association (ADA), taking place 10- 14 June 2016 in New Orleans, the United States. This is the first time results from these pivotal trials are being presented at a scientific congress.
Further at ADA, Zealand will present new data from its proprietary preclinical activities, including on a novel peptide drug candidate from its preclinical pipeline.
Abstracts of the ADA presentations are available at: http://app.core-apps.com/tristar_ada16
IGlarLixi – Oral presentations of results from two pivotal Phase III trials, LixiLan-O and LixiLan-L
Presentation of results from LixiLan-O (# 186-OR):
“Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial”
When: Sunday, 12 June 2016 at 8.45 am CDT
Presenter: Julio Rosenstock, MD, Dallas Diabetes and Endocrine Center
Location: La Nouvelle Orleans AB
Link to abstract: http://app.core-apps.com/tristar_ada16/event/2dcea2d3f4cca64c82bb162014ab0feb
Presentation of results from LixiLan-L (# 238-OR):
“Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The LixiLan-L Trial”
When: Sunday, 12 June 2016 at 2.30 pm CDT
Presenter: Vanita R. Aroda, MD, Medstar Health Research Institute
Location: La Nouvelle Orleans AB
Link to abstract: http://app.core-apps.com/tristar_ada16/event/9b73fdfd4b7befbd3fa1b130a88c5086
Zealand poster presentations
Zealand scientists will present posters with new data from two of the company’s proprietary preclinical peptide drug projects:
“Antidiabetic Effects of Novel, Long-Acting Amylin Analogue ZP4982 in ZDF Rats” (# 283-LB)
When: 12 June 2016 at 12 pm CDT
Presenter: Jolanta Skarbaliene, Zealand, Denmark
Location: Poster Hall (D-E)
Link to abstract: http://app.core-apps.com/tristar_ada16/abstract/e44e3c20f4b9cf62bd1796c12c19074b
“Model of the Glucose-Insulin-Glucagon Dynamics after Subcutaneous Administration of a Glucagon Rescue Bolus in Healthy Humans” (# 1759-P)
When: 12 June 2016 at 12 pm CDT
Presenter: Sabrina L. Wendt, Zealand, Denmark
Location: Poster Hall (D-E)
Link to abstract: http://app.coreapps.com/tristar_ada16/abstract/92b0eac0f984437a5bebc08c57a7b135
